Pharma BD Deal Intelligence
This will be the most significant acquisition in the Company's history. The generic and branded businesses of Cypress and Hawthorn are an excellent fit for…
Factual completion coverage: Pernix completed the acquisition of Cypress Pharmaceutical and Hawthorn Pharmaceuticals under the terms announced November…
Zacks framed the closed deal as a transformative two-for-one transaction adding generics scale plus a branded portfolio to Pernix's pediatric-cough base.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Pernix acquired Cypress Pharmaceuticals (private generics) and Hawthorn Pharmaceuticals for up to $102M ($52M cash + $34M equity upfront, plus contingent payments). Strategic doubling-down in specialty pharmaceuticals.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pernix Therapeutics Holdings, Inc. / Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. (this deal) | 2012 | $102M | 21 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2012 deals · Other deals